Home/Pipeline/UB-311

UB-311

Alzheimer's Disease

Phase 2Active

Key Facts

Indication

Alzheimer's Disease

Phase

Phase 2

Status

Active

Company

Vaxxinity

About Vaxxinity

Vaxxinity (NASDAQ: VAXX) is a U.S.-based biotech firm with a mission to democratize healthcare through its proprietary Active Immunotherapy Medicine (AIM) platform. The company has achieved significant validation, including a successful Phase 3 trial for a COVID-19 booster and billions of doses commercialized in animal health, underpinning its strategy to develop long-acting, scalable therapies for large markets like Alzheimer's and hypercholesterolemia. Its core differentiator is the ability to safely break immune tolerance against self-antigens, a key hurdle in chronic disease treatment, using a synthetic, low-cost peptide approach that requires no frozen cold chain.

View full company profile

Therapeutic Areas

Alzheimer's Disease Hypercholesterolemia COVID-19 Parkinson's Disease Migraine

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
Alzheimer's program	Risen Pharma Tech	Clinical (China & US)	Active